Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Study Identifier:
PB-102-F90
ClinicalTrials.gov Identifier:
NCT04552691
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Fabry Disease
Study Drug
  • Drug: Pegunigalsidase Alfa
Date
N/A - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • In the opinion of the Treating Physician, the patient cannot be adequately treated with any FDA approved drugs for Fabry and is not able to enroll in any current clinical trial for Fabry disease.
  • Patient (or legal guardian) is able to sign an informed consent prior to treatment.
  • A documented diagnosis of Fabry disease.
  • Preferably two, but at minimum 1, historical serum creatinine evaluations in the last 2 years with the latest value within the last 6 months.
  • Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically acceptable method of contraception, not including the rhythm method. Acceptable methods of contraception include hormonal products, intrauterine device, or male or female condoms. Contraception should be used for 90 days after treatment discontinuation.
Exclusion Criteria
  • Patients enrolled and currently treated in Study PB-102-F20, and patients enrolled and currently treated in Extension Study PB-102-F60
  • Patients who currently are on treatment under any other ongoing clinical trials of PRX-102
  • History of Type 1 (anaphylaxis or anaphylactoid like) life-threatening hypersensitivity during previous exposure to other ERTs which could not be handled with medication
  • Women who are breastfeeding may not participate unless they agree to stop breastfeeding.
  • Women who are currently pregnant.
Healthy Volunteers
No

Protocol Summary

The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires treatment with enzyme replacement therapy (ERT) with pegunigalsidase alfa and a) cannot be adequately treated with currently approved FDA products and/or b) are not able or willing to participate in any of the on-going clinical trials in the United States.

Study Locations

Location
Status
Location
University of Alabama-Birmingham
Birmingham, Alabama, United States, 35294
Status
N/A
Location
Phoenix Children's Hospital, Inc.
Phoenix, Arizona, United States, 85006
Status
N/A
Location
University of California Irvine
Orange, California, United States, 92868
Status
N/A
Location
Central Coas Nephrology
Salinas, California, United States, 93901
Status
N/A
Location
University of Florida, Division of Pediatric Genetics
Jacksonville, Florida, United States, 32207
Status
N/A
Location
Emory University School of Medicine
Atlanta, Georgia, United States, 30322
Status
N/A
Go to page